Photoaffinity labeling (PAL) using a #chemical probe to covalently bind its target in response to activation by light has become a frequently used tool in #drugdiscovery. Based on PAL, ChomiX has developed a technical platform for chemoproteomic profiling protein targets for noncovalent small molecule drugs. Non-covalent interactions, such as hydrogen bonds and π-π stacking, can be disrupted due to #protein denaturation. To address this challenge, our platform employs photoaffinity labeling to precisely attaching "chemical labels" to a protein's active site. Furthermore, our innovative in situ chemical crosslinking strategy transforms transient non-covalent protein interactions into covalent and permanent chemical bonds. By utilizing a chemical probe that is functionalized with both photoaffinity and bioorthogonal moieties, ChomiX's chemoproteomics platform has demonstrated its effectiveness in successfully fishing out protein targets within cell lysates, tissues, and living cells. The spectrum of bioactive small molecule drugs applied in the platform encompasses a variety of compounds, including endogenous metabolites, #naturalproducts, and non-covalent synthetic molecules.
ChomiX Biotech’s Post
More from this author
-
Exploring the application of chemical proteomics technology in lung cancer research
-
Genetically Encoded Epoxide Warhead for Precise and Versatile Covalent Targeting of Proteins
-
Targeted therapy and interdisciplinary exploration of metabolic diseases: a new direction in research on post-translational modifications